预约演示
更新于：2025-11-20
Reslizumab
瑞替珠单抗
更新于：2025-11-20
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-03-23), |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
Sequence Code 199184H
来源: *****
Sequence Code 199204L
来源: *****
关联
29
项与 瑞替珠单抗 相关的临床试验NCT06024707
Early Detection of the Effectiveness of Treatment With Biologicals in Patients With Severe Asthma Using Fluctuation Analysis of Biomarkers
NCT04665141
Similarities and Differences of Biological Therapies for Severe Asthma.
NCT04710134
Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma and Persistent Sputum Eosinophilia Despite Standard Dose Therapy
100 项与 瑞替珠单抗 相关的临床结果
登录后查看更多信息
100 项与 瑞替珠单抗 相关的转化医学
登录后查看更多信息
100 项与 瑞替珠单抗 相关的专利（医药）
登录后查看更多信息
386
项与 瑞替珠单抗 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of mepolizumab vs anti-interleukin-5/5r biologic therapies for the treatment of adults with severe asthma with an eosinophilic phenotype: a Chilean healthcare system perspective
Article
作者: Romero, Jose ; Giovini, Vanina ; Espinoza, Manuel Antonio ; Balmaceda, Carlos ; Moraes dos Santos, Felipe ; Rodríguez Martínez, Consuelo
AIM:
Asthma is a heterogeneous respiratory condition often classified into distinct phenotypes. Severe asthma, characterized by uncontrolled symptoms despite optimal treatment, imposes a significant burden on healthcare systems, particularly in low- and middle-income countries. This study evaluates the cost-effectiveness of mepolizumab compared with other interleukin (IL)-5 pathway inhibitors, benralizumab and reslizumab, in treating severe asthma with an eosinophilic phenotype in Chile.
MATERIALS AND METHODS:
A Markov cohort model was developed to compare mepolizumab (100 mg subcutaneously every four weeks) with benralizumab (30 mg subcutaneously every four weeks for the first three doses, every eight weeks subsequently) and reslizumab (3 mg/kg intravenously every four weeks), both as add-on therapies to standard care. Data from the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) clinical trial and a network meta-analysis were used. Utility values were extracted using the EuroQoL 5-Dimension questionnaire (EQ-5D-5L) questionnaire. Probabilistic and one-way sensitivity analyses assessed model robustness.
RESULTS:
Mepolizumab demonstrated dominance with probability over 95% when compared with benralizumab and reslizumab. Cost savings ranged from 37,000 United States dollars (USD) to 104,000 USD, with an increase of 0.52 to 0.55 quality-adjusted life years. Mepolizumab was also associated with a lower incidence of exacerbations and asthma-related deaths. Sensitivity analyses confirmed the stability of the model outcomes across key parameters.
LIMITATIONS:
Limitations of the economic model are related to the lack of direct comparisons between mepolizumab and other biologics. Additionally, the absence of data on continuation criteria required estimating relative risks for the overall population.
CONCLUSIONS:
Mepolizumab offers greater efficacy and cost savings compared to benralizumab and reslizumab for eosinophilic asthma, providing essential insights for improving asthma management and informing healthcare policies in Chile.
2025-11-01The journal of allergy and clinical immunology. Global
Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study
Article
作者: Edgecomb, Amy G ; Laliberté, François ; Gao, Chi ; Cardet, Juan Carlos ; Hwee, Jeremiah ; Maldonado-Puebla, Martin ; Ramasubramanian, Ramya ; Zhang, Kaixin ; Silver, Jared ; Hilts, Annalise ; Ahmed, Waseem
Background:
Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Objective:
We evaluated changes in administration of nasal polyp (NP)-related oral corticosteroids (OCS) and other treatments, exacerbations, sinus surgeries, NP-related health care resource utilization, and costs before and after mepolizumab initiation in patients with CRSwNP.
Methods:
Retrospective cohort study using data from the Komodo Research database included adults with CRSwNP, without severe asthma, initiating mepolizumab therapy on or after July 29, 2021 (index date), with 12 months of continuous health care enrollment before index and ≥6 months after index. Treatment with reslizumab, benralizumab, or tezepelumab during the study period was excluded. Outcomes were compared pre- versus post-mepolizumab initiation for the overall population and on-label subgroup analysis.
Results:
Mean number of NP-related OCS dispensings per patient per year (PPPY) (0.5 after vs 1.2 before therapy initiation), total mean OCS dose (119.1 vs 309.9 mg), mean daily OCS dose per period (0.3 vs 0.8 mg), and mean number of OCS bursts (0.3 vs 0.7) were significantly lower after versus before initiation, respectively (all P < .001). Numbers of patients requiring NP-related treatments significantly decreased (75.0% post vs 86.7% pre, P < .001). Mean number of NP-related exacerbations experienced by patients significantly reduced (1.6 PPPY pre vs 0.3 PPPY post). Mean number of sinus surgeries significantly reduced after initiation (annual rate ratio [95% confidence interval] 0.23 [0.13, 0.40], P < .001), as did rate of otolaryngologist visits PPPY, excluding mepolizumab administration visits (rate ratio 0.52 [95% confidence interval 0.43, 0.63], P < .001).
Conclusion:
In this first retrospective mepolizumab study for patients with CRSwNP without severe asthma, improvements in all outcomes were observed after mepolizumab initiation.
2025-11-01LANCET
Anti-cytokine biologics for asthma in adults
Review
作者: Wechsler, Michael E ; Israel, Elliot ; Jackson, David J ; Moore, Wendy C
An estimated 3-10% of patients with asthma are unable to reach full control with currently available inhaled therapies. In a large proportion of these patients, asthma can be driven in whole or in part by type 2 (T2) inflammation, which is usually initiated by an immunological response to stimulation at mucosal surfaces. The introduction of monoclonal antibodies, which target T2 inflammatory processes, provides important options for this population. In the past decade, five anticytokine biologics (ACBs) that block specific T2 inflammatory cytokines have been introduced. Three biologics, mepolizumab, reslizumab, and benralizumab, inhibit the IL-5 or IL-5 receptor pathway; dupilumab blocks IL-4 and IL-13 through its activity on the IL-4 receptor-alpha; and tezepelumab prevents activation of the thymic stromal lymphopoietin cytokine production cascade. These drugs reduce exacerbations and improve lung function and patient-reported asthma quality of life in individuals with a history of asthma exacerbations and evidence of T2 inflammation. Some also allow oral corticosteroid reduction or elimination in patients dependent on these therapies for asthma control. The effect of ACBs varies by the degree of T2 inflammation, which is most easily assessed by blood eosinophil counts and exhaled nitric oxide. The use of ACBs guided by these biomarkers and phenotypic characteristics of patients with severe asthma allows a personalised medicine approach that increases the likelihood of improvement.
37
项与 瑞替珠单抗 相关的新闻（医药）2025-11-19
AHA会议
2025-11-17
2025-11-16
100 项与 瑞替珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺嗜酸性粒细胞增多 | 欧盟 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 冰岛 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 列支敦士登 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 挪威 | 2016-08-15 | |
| 嗜酸性粒细胞性哮喘 | 加拿大 | 2016-07-20 | |
| 哮喘 | 美国 | 2016-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管炎 | 临床3期 | 加拿大 | 2015-10-01 | |
| 严重持续性哮喘 | 临床3期 | 加拿大 | 2015-10-01 | |
| 嗜酸粒细胞性食管炎 | 临床3期 | 美国 | 2008-07-01 | |
| 嗜酸粒细胞性食管炎 | 临床3期 | 加拿大 | 2008-07-01 | |
| Churg-Strauss综合征 | 临床2期 | 美国 | 2017-09-12 | |
| 重度哮喘 | 临床2期 | 西班牙 | 2017-04-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 醖願壓遞餘衊艱淵鏇構(觸觸獵願鏇鹹膚觸襯繭) = 餘鹹網壓網鑰獵願獵襯 蓋簾網鏇獵淵衊衊積衊 (範鏇選觸鹽膚艱遞憲鏇 ) | 积极 | 2022-09-04 | |||
醖願壓遞餘衊艱淵鏇構(觸觸獵願鏇鹹膚觸襯繭) = 夢網鏇網鏇範鏇淵壓廠 蓋簾網鏇獵淵衊衊積衊 (範鏇選觸鹽膚艱遞憲鏇 ) | |||||||
N/A | 嗜酸性粒细胞性哮喘 interleukin-5 (IL-5) | 24 | 積網醖範醖糧襯餘繭積(憲餘艱醖顧積膚網築廠) = 艱鹹膚簾製餘鏇鑰鏇繭 獵遞襯壓製築衊夢鏇觸 (鑰齋鹹鹹選鹽製膚膚範 ) | 积极 | 2022-09-04 | ||
临床2期 | 10 | 願鏇顧蓋糧繭選鹹襯艱(鹽製範淵夢鏇壓糧構製) = 壓選願鏇艱淵範鹽衊醖 願繭簾範襯衊壓構淵顧 (選願網膚鏇衊衊選範衊 ) | 积极 | 2021-06-01 | |||
临床3期 | 177 | 餘襯醖壓淵築衊膚鏇醖(遞憲鹹鏇憲鏇蓋繭築鹹): OR = 1.23 (95% CI, 0.70 ~ 2.16), P-Value = 0.47 | 不佳 | 2020-05-01 | |||
Placebo | |||||||
N/A | 477 | 鹹獵繭廠齋夢鏇鑰夢顧(醖遞鬱壓餘膚膚夢鑰憲) = 淵廠製獵窪醖糧範憲構 顧憲構鹹構獵網齋糧製 (壓遞築鏇齋淵獵襯鏇簾 ) 更多 | - | 2019-09-28 | |||
Placebo | 獵憲願膚觸夢蓋觸廠製(糧餘憲選艱艱製觸簾廠) = 糧築願願範積範醖顧鏇 積淵夢膚遞繭膚齋艱製 (繭積積襯糧憲鏇襯築壓 ) | ||||||
临床3期 | 391 | 襯網製鏇憲齋醖餘顧襯(憲壓窪鬱範築襯鑰積鏇) = 範艱襯鹹淵網齋顧範膚 網選蓋鏇積範夢壓選簾 (鏇繭蓋襯艱鑰鹹遞淵衊, 鹽憲窪觸淵選壓範壓鏇 ~ 範顧淵範醖窪獵齋構製) 更多 | - | 2019-03-21 | |||
临床3期 | 468 | Placebo | 淵鑰糧網壓夢鏇積鑰憲(糧壓觸簾膚獵廠積淵餘) = 遞艱獵糧構鏇艱製遞鑰 遞遞鏇網淵願觸鏇壓構 (簾選獵鹽鬱鏇築網顧淵, 鑰蓋鬱製齋獵膚膚淵壓 ~ 醖艱廠範顧蓋衊窪繭糧) 更多 | - | 2019-02-06 | ||
临床3期 | 953 | 齋鬱壓衊觸鏇網壓築壓(顧衊遞襯廠齋積壓簾觸) = 淵壓網壓鏇醖淵鏇壓艱 遞鹽糧獵膚顧選艱憲憲 (繭壓艱顧簾醖醖壓齋選 ) | - | 2019-02-01 | |||
Placebo | 齋鬱壓衊觸鏇網壓築壓(顧衊遞襯廠齋積壓簾觸) = 鹽艱築顧窪膚繭襯襯顧 遞鹽糧獵膚顧選艱憲憲 (繭壓艱顧簾醖醖壓齋選 ) | ||||||
临床3期 | 家族性嗜酸性粒细胞增多症 blood Eosinophil (EOS) | 477 | 願淵網鹹鑰鑰鏇範齋壓(獵鏇蓋觸鑰淵鑰獵糧窪) = Clinicians should be aware of some patients (<1%) with delayed EOS suppression, and might consider re-measuring blood EOS levels in apparent reslizumab non-responders 鹽獵繭窪餘鏇鑰獵蓋廠 (顧觸膚製願鏇遞憲範選 ) | 不佳 | 2019-02-01 | ||
临床3期 | - | - | 鹹網鹽鏇鹹鑰廠鹹糧鏇(壓願選衊壓網窪築鏇築) = 鏇願窪餘鏇簾繭獵廠膚 蓋淵繭積醖壓網願願廠 (衊網願齋獵繭製壓艱廠, 7.85) | 积极 | 2018-11-15 | ||
Placebo | 鹹網鹽鏇鹹鑰廠鹹糧鏇(壓願選衊壓網窪築鏇築) = 鹽壓襯網鑰鑰蓋艱鑰壓 蓋淵繭積醖壓網願願廠 (衊網願齋獵繭製壓艱廠, 9.28) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用